Vantictumab

Vantictumab
Monoclonal antibody
Type	?
Source	Human
Target	Frizzled receptor
Clinical data
Routes of; administration	IV
ATC code	none;
Identifiers
CAS Number	1345009-45-1;
ChemSpider	none;
UNII	88WBI2D80S;
KEGG	D10410;
Chemical and physical data
Formula	C6322H9722N1674O1988S46
Molar mass	142461.81 g·mol−1

Vantictumab /vænˈtɪktʊmæb/ is a human IgG2 monoclonal antibody designed for the treatment of cancer.[1]

This drug was developed by OncoMed Pharmaceuticals Inc. in partnership with Bayer.[2] OncoMed was awarded a patent in 2016, which is set to expire in 2029.[3] In April 2017, Bayer terminated its option to license vantictumab.[4]

It inhibits wnt signalling by targeting the frizzled receptors on cancer cells.[5]

Phase I trials have been completed for pancreatic cancer, non-small cell lung cancer, and breast cancer. In 2016 results were reported from a phase 1b clinical trial for triple-negative breast cancer[5][6] and in 2020 for pancreatic cancer.[7]

References

"Statement on a nonproprietary name adopted by the USAN Council" (PDF). AMA. 28 Nov 2012. N12/155.(registration required)
"OncoMed Pre-Announces 2014 Year-End Cash Balance and Provides 2015 Guidance". 12 January 2015.
"Annual Report on Form 10-K". OncoMed Pharmaceuticals, Inc. Archived from the original on 13 January 2017.
"BRIEF-Oncomed Pharmaceuticals announces Bayer terminates its option to license vantictumab or ipafricept". Reuters. 10 April 2017.
"Finally, targeted therapies for triple-negative breast cancer". Medical Xpress. June 2016.
Diamond JR, Becerra C, Richards D, Mita A, Osborne C, O'Shaughnessy J, et al. (November 2020). "Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer". Breast Cancer Research and Treatment. 184 (1): 53–62. doi:10.1007/s10549-020-05817-w. PMC 7572714. PMID 32803633.
Davis SL, Cardin DB, Shahda S, Lenz HJ, Dotan E, O'Neil BH, et al. (June 2020). "A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer". Investigational New Drugs. 38 (3): 821–830. doi:10.1007/s10637-019-00824-1. PMC 7211194. PMID 31338636.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[vantictumab_usan-1] "Statement on a nonproprietary name adopted by the USAN Council" (PDF). AMA. 28 Nov 2012. N12/155.(registration required)

[2] "OncoMed Pre-Announces 2014 Year-End Cash Balance and Provides 2015 Guidance". 12 January 2015.

[3] "Annual Report on Form 10-K". OncoMed Pharmaceuticals, Inc. Archived from the original on 13 January 2017.

[4] "BRIEF-Oncomed Pharmaceuticals announces Bayer terminates its option to license vantictumab or ipafricept". Reuters. 10 April 2017.

[2016-1b-5] "Finally, targeted therapies for triple-negative breast cancer". Medical Xpress. June 2016.

[pmid32803633-6] Diamond JR, Becerra C, Richards D, Mita A, Osborne C, O'Shaughnessy J, et al. (November 2020). "Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer". Breast Cancer Research and Treatment. 184 (1): 53–62. doi:10.1007/s10549-020-05817-w. PMC 7572714. PMID 32803633.

[pmid31338636-7] Davis SL, Cardin DB, Shahda S, Lenz HJ, Dotan E, O'Neil BH, et al. (June 2020). "A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer". Investigational New Drugs. 38 (3): 821–830. doi:10.1007/s10637-019-00824-1. PMC 7211194. PMID 31338636.